Exclusive interview with Alex Zhavoronkov
Insilico CEO on spreading the longevity message – the time is now. Dr Alex Zhavoronkov is the CEO and co-founder …
Continue reading “Exclusive interview with Alex Zhavoronkov”
Insilico CEO on spreading the longevity message – the time is now. Dr Alex Zhavoronkov is the CEO and co-founder …
Continue reading “Exclusive interview with Alex Zhavoronkov”
The “MMA fighter” of Longevity talks business models, AI drug discovery and working with the right investors. Dr Alex Zhavoronkov …
Continue reading “Insilico’s Dr Alex Zhavoronkov defines Longevity”
Dr Feng Ren, Chief Scientific Officer (CSO) and head of global research and development is set to leverage his GSK …
Continue reading “Insilico appoints co-CEO in readiness for clinical data test”
Insilico Medicine’s $60 million Series D financing raise will see the AI-driven drug discovery company advance its pipeline. Insilico Medicine, …
Longevity was one of the most talked about industries on the streets of Davos during this year’s World Economic Forum …
Continue reading “Longevity takes over Davos – and has Gstaad in its sights”
Leaders in the aging and longevity field will describe the latest progress in the molecular, cellular and organismal basis of …
Continue reading “9th ARDD packed with more than 70 leaders in aging and longevity”
Deep Longevity – on a mission to extend healthy productive longevity and increase human performance. Over the coming weeks, we …
Continue reading “Deep Longevity – extending longevity and increasing human performance”
Identifying dual-purpose therapeutic targets that are implicated in aging and disease will extend healthspan and delay age-related health issues. Insilico …
New collaboration leverages Insilico’s end-to-end discovery platform and EQRx’s innovative business model to accelerate drug development. Insilico Medicine has announced …
Continue reading “Insilico announces strategic collaboration for AI-driven drug discovery”